preview dont look controversi ep
result proxi clinic data could surpris
messag preview overal outlook global pharma coverag
univers point mostli in-lin sale ep result said weve increas
pt azn vs reflect busi momentum recent dsnki
collabor vs given keytruda momentum novo vs
dkk physician enthusiasm oral semaglutid ozemp continu build
main event pharma vote bmy/celg agn proxi
challeng jnj credenc data novn
novo gip/glp data ada
expect pharma result broadli line expect across coverag
area interest diabet competit dynam evolut
categori lli trulic well novo ozemp victoza ahead potenti
launch novo oral semaglutid late oncolog still competit
dynam see keytruda growth continu unab investor
look intern market upsid vs consensu question around
evolut kidney cancer market abound competit growth within chronic
migrain market remain focu particularli growth anti-cgrp class appear
paus drama novarti aimovig add question
beyond categori impact agn botox
what hot alway chock full data year diabet look like
domin week april schedul present credenc data
studi inhibitor invokana drug benefit prevent kidney
diseas progress seriou cardiac event patient type diabet chronic
kidney diseas kol believ result could spur inflect use lli
jardianc azn farxiga possibl resurrect jnj invokana beyond next
week nephrolog meet cardiovascular dataset ada june lli trulic
rewind novo oral semaglutid pioneer like cement
class must treatment type diabet focu novn
intensifi approv approach may expect novn reveal first
data use intrathec dose older sma patient given rapidli rise consensu sale
expect approv label expect rel broad label
like appli type patient mo age price critic
novn guidanc pace trajectori launch key within oncolog expect
rel quiet await headlin result bmi part
overal surviv opdivo yervoy vs chemotherapi patient part
page analyst certif import disclosur
there shortag potenti controversi bmy/celg vote
balanc believ sharehold vote support bmy/celg transact
howev base interact investor believ vote extrem
close perhap favor appaloosa proxi challeng separ role chairman
ceo sharehold vote favor separ role path forward agn
board ceo unclear continu see signific opportun unlock trap
valu current level
page analyst certif import disclosur
page analyst certif import disclosur
allergan global pharmaceut compani incorpor ireland market-lead posit medic aesthet
neurosci women health ophthalmolog gastroenterolog
consensu forecast deliv sale oper margin adjust basi consensu
expect busi grow compound-annual-growth-rate
domin medic aesthet w/ botox juvederm coolsculpt compani largest franchis sale
expect global facial inject market doubl
therapeut growth driver includ botox therapeut legaci forest product viibryd depress vraylar antipsychot
page analyst certif import disclosur
gsr vs consensu million except ep
forecast sale ep
respect line consensu given expect
gener entri restasi earliest forese anoth solid
sale ep perform despit declin volum see
legaci product
sale estim upper end agn full year
guidanc consensu estim like
due slower gener restasi eros curv assumpt vs
consensu accordingli ep estim also
consensu ep estimate
forecast botox sale y/i growth expect
botox migrain growth slow uptak amgn/novn
teva anti-cgrp antibodi launch last year migrain
us rx analysi million
focu call
think invest depress space post-
rapastinel busi develop opportun
space could bolster categori beyond vraylar
physician say risk/benefit profil abicipar
modifi formul rate inflamm rel origin
formul opportun that underappreci
street
avail anti-cgrp antibodi see
far new patient start botox migrain see
meaning chang prescrib habit overal expect
chang move forward base trend your see
discuss atogep posit prophylaxi treatment migrain
guggenheim secur llc estim compani report factset note unit except ep
rel anti-cgrp antibodi
page analyst certif import disclosur
vs million except ep
forecast agn total sale increas
reflect compound-annual-growth-rate sale expect
mainli driven steadi growth aesthet busi
enough off-set revenu declin due loe restasi
expect sale growth slow
compound-annual-growth-rate due flat growth medic aesthet faster
sale declin associ loe mainli eye care busi
forecast pipelin contribut offset
eros base busi mainli come ophthalmolog
particular estim oral cgrp relamorelin contribut
combin sale
consensu ev/ebit
guggenheim secur llc estim compani report factset note unit except ep
botox fare well face neurotoxin similar
face new competit jeuveau potenti longer
act neuromodul daxibotulinumtoxina
strategi put place ensur botox maintain
domin aesthet market
relamorelin phase gastroparesi view next
major catalyst remind challeng
space fda evok gimoti much input
fda relamorelin trial design relamorelin
avoid clinic develop pitfal plagu previou
agn oral cgrp program affect anti-cgrp
migrain prevent oral cgrp biohaven select
oral lasmiditan acut migrain
page analyst certif import disclosur
posit view reflect
sustain leadership medic aesthet botox juvederm coolsculpt
double-digit growth key line growth product vraylar
posit risk/reward high impact catalyst pipelin agent abicipar wet new formul
long-term pipelin option relamorelin novel agent diabet gastroparesi
attract valuat rel global pharma peer
valu share base blend dcf analysi valu base sale thru
wacc consist discount rate use global pharma co termin growth vs
global pharma reflect cost agn open scienc strategi base case sum part analysi sotp valu
botox use declin due cgrp mab
clinic failur atogep relamorelin
page analyst certif import disclosur
note valu million except price
page analyst certif import disclosur
financi modelcagrcagr usd million except total gross total total oper incom pre-tax incom tax net incom dilut share dilut incom incom growth profit global
azn busi overview potenti catalyst
astrazeneca uk-bas biopharmaceut compani oper broad rang therapeut categori includ oncolog
respiratori cardiovascular diseas neurosci
consensu forecast azn deliv sale reflect yoy growth
azn compani transit near tail-end signific loe period primari care busi look return
growth flagship oncolog franchis imfinzi tagrisso partner oncolog collabor includ lynparza
next month azn number potenti catalyst includ key data readout product anemia prostat
breast lung cancer well leukemia nearest potenti stock-mov event pool safeti data roxadustat
page analyst certif import disclosur
forecast sale ep
respect line consensu driven growth
expect azn deliv total revenu
ep modestli consensu sale
ep
base analysi us volum trend expect diabet
product farxiga bydureon come rel line
forecast tagrisso continu show strong momentum
y/i growth sequenti growth brilinta also good
perform quarter expect contd strong growth
iqvia/symphoni script analysi us sale
focu call
what opportun low cancer given
antibodi trastuzumab like herceptin
make effect low tumor kadcyla
discuss impact import show superior safeti profil
roxadustat would justifi launch drug global
ckd safeti isnt superior
calquenc updat time head-to-head result
remind us time tezepelumab anti-tslp phase
result given ownership fasenra deal
tslp data would necessari justifi
preferenti shift resourc tslp
guggenheim secur llc estim compani report factset iqvia symphoni health price rx note unit except ep
page analyst certif import disclosur
new model includ collabor revenu daiichi
sankyo profit-shar agreement forecast sale
dilut ep lower overal consensu sale
dilut ep despit consensu
estim opex lower consensu
consist azn commit improv
oper margin line industri peer
assum sustain double-digit sale growth azn
launch product versu consensu bullish sale
tagrisso fasenra lynparza calquenc
higher consensu respect street roughli
line imfinzi forecast
azn consensu ev/ebit
guggenheim secur llc estim compani report factset note unit except ep
low cancer think
greatest impact due lower bar/less competit
opportun combin therapi
quickli advanc pivot trial
opportun excit imfinzi
given efficaci imfinzi monotherapi mystic
patient group hazard ratio similar mrk keytruda
similar popul what opportun imfinzi
chemotherapi poseidon
structur kind margin improv possibl azn
page analyst certif import disclosur
posit view azn reflect
high-single-digit sale double-digit ep growth
continu leadership respiratori diseas pipelin product fasenra tezepelumab
success proof cv overal safeti near-term high risk/high reward opportun roxadustat anemia
partial off-set continu relianc extern revenu support cash flow oper margin view azn low
oper margin pois substanti improv new product portfolio continu expand global
given busi momentum recent dsnki collabor dcf valuat azn rais
base wacc line compani coverag univers termin growth
worsen access price diabet respiratori
surpris safeti develop roxadustat calquenc prove inferior efficaci imbruvica
failur loss efficaci larger trial
page analyst certif import disclosur
note valu million except price
page analyst certif import disclosur
financi modelcagrcagr usd million except product oper incom pre-tax incom tax net incom adr share dilut incom incom growth profit global
us-bas global pharmaceut compani focus immuno-oncology/oncolog immunolog cardiovascular fibrot
consensu estim bmi sale adjust oper margin
opdivo immuno-oncolog therapi eliqui anticoagul compani largest product growth driver
combin sale bmi total revenu
recent announc celg acquisit materi could provid signific ep accret free cash flow near middl
page analyst certif import disclosur
establish celg nj base large-cap biotech compani special hematology/oncolog inflamm immunolog
consensu estim celg sale adjust oper margin celg hematology/oncolog
branch expect contribut total sale inflammation/immunolog unit expect contribut rest
revlimid oral immunomodulatori agent compani lead product growth driver global sale
celg total revenu market penetr expect label expans consensu forecast sale
world-wide revlimid current face ip challeng rdi potenti earlier gener eros risk
celg five near-launch pipelin drug car-t therapi liso-cel accord propos bmy-celg
deal celg investor receiv tradabl cvr redeem one-tim payment ozanimod liso-cel
approv approv
relaps refractori multipl
page analyst certif import disclosur
forecast sale ep respect
line consensu estim sale
ep sale mainli driven uptak opdivo/yervoy
eliqui partial off-set fx headwind
sale includ cer revenue growth line
bmi mid-singl digit sale growth guidanc ep
higher consensu estim management ep guidanc
base us volum demand price analysi eliqui
meet sale estimate given strong yoy growth qoq growth
respect opdivo could come ahead us given
scripts/sal disconnect keep estim
script analysi us sale
focu call
provid updat checkmate- opdivo
cabozantinib vs sunitinib bmi view evolv
rcc market next year given recent success
dataset inform potenti therapi
alon treatment implic
last month novn mayzent approv select
receptor modul ms includ spm
compani see key advantage/differenti ozanimod
enter ms market therapi drug class
guggenheim secur llc estim compani report factset iqvia symphoni health price rx note unit except ep
page analyst certif import disclosur
expect growth innov drug opdivo eliqui
drive sale reflect
compound-annual-growth-rate accordingli bmi ep show similar growth
trend increas
stand-alon growth reflect declin
reach mainli due loe key asset eliqui
sprycel orencia account combin sale reduct
estim
forecast total sale pipelin drug bms-
inhibitor partial offset larg
sale declin due loe justifi bmi effort
replenish pipelin intern extern
stand-alone consensu ev/ebit
guggenheim secur llc estim compani report factset note unit except ep
evolut adjuv neoadjuv treatment cancer
seen next larg opportun io develop
posit neoadj/adj treatment solid tumor
see major inflect point growth
remain opportun nsclc assum success
one come lung cancer ph trial
inhibitor abl replic impress
ph efficacy/safeti data ph trial obtain approv
psoriasi larg commerci potenti
psoriasi relev immun disord oral small molecul
drug biologic-lik efficaci proven ph clinic trial
page analyst certif import disclosur
leadership posit immuno-oncolog opdivo yervoy expect intensifi competit
roch azn result rapid growth slowdown least end
mid-single-digit sale ep growth mix busi limit margin leverag period
develop pipelin includ late-stag asset ph increasingli competit categori
psoriasi follow predominantli high-risk/high-reward ph develop pipelin
potenti acquisit celg risk revlimid ip disput
fair valu rang forecast sale profit use larg pharmaceut compani discount rate
line compani coverag univers termin growth rate
success develop opdivo combin lung cancer better-than-expect opdivo/relatlimab
disappoint ph result competitor i/o trial particularli rhhbi
better-than-expect ph result i/o competitor
clinic failur mid- late-stag pipelin program
page analyst certif import disclosur
page analyst certif import disclosur
financi modelcagrcagr usd million except innov gross oper incom incom /expens pre-tax incom tax net incom dilut share dilut incom incom growth profit global
 base global pharmaceut compani headquart indianapoli indiana follow equiti carv
oper pure-play human pharmaceut compani
consensu forecast sale grow reflect compound-annual-growth-rate
diabet lli largest segment expect street reach sale repres total sale
estim driven growth franchis
next month key potenti catalyst includ detail data tanezumab safeti efficaci osteoarthr chronic
back pain well addit ph data olumi baricitinib atop dermat
page analyst certif import disclosur
gsr vs consensu million except ep
forecast exclud elanco follow sale
lli stake sale forecast
consensu
like analyst estim still includ
sale op margin estim
respect line management guidanc
sale op margin pharma busi
base iqvia/symphoni sale trend think taltz least
meet estim given yoy growth qoq
growth insulin continu see price declin expect
price novel diabet therapi trulic jardianc remain
stabl
iqvia/symphoni script analysi us sale
focu call
note unit except ep
label discuss fda rewind
result could potenti new updat look like
benefit medium- long-term growth trulic
management guidanc impli pretti meaning step-up achiev
guidanc management previous guid
help us understand push pull get
discuss lli experi far payer
get emgal onto formulari biggest
challeng get access drug major payer
could help us understand detail ip disput lli
institut ipr disput teva potenti impact
page analyst certif import disclosur
vs million except ep
forecast sale grow
repres compound-annual-growth-rate driven growth trulic
jardianc immunolog franchis despit sale eros
due expect loe alimta forteo
expect sale growth moder
compound-annual-growth-rate partial due declin legaci insulin product
potenti biosimilar competit trulic
forecast lli pipelin contribut
driven lli dual agonist
forecast launch estim
sale
consensu ev/ebit
evolut price space risk
fastest grow categori diabet categori continu
grow becom competit current price disciplin
access maintain
weight loss benefit seen anti-diabet agent
particularli analog replic move phase
phase implic
increment impact loxo armo transact
look like rel current expect
investor need see detail dataset later year
gain comfort around commerci opportun tanezumab
guggenheim secur llc estim compani report factset note unit except ep
page analyst certif import disclosur
view support
price disciplin major shift payer toward exclus formulari continu benefit trulic
commerci clinic success potenti blockbust pain drug emgal anti-cgrp migrain prophylaxi
continu execut market lead fast-follow drug develop
off-set impact alimta forteo potenti safeti risk tanezumab increas competit jardianc
trulic potenti challeng diabet pricing/reimburs environ
fair valu rang reflect forecast sale profit use larg pharmaceut
compani discount rate termin growth rate
upsid risk valuat includ
trulic jardianc sale meaning estim
sustain price pressur diabet immunolog
higher-than-expect rate seriou advers event rpoa long term safeti studi tanezumab detail data
page analyst certif import disclosur
page analyst certif import disclosur
financi modelcagrcagr usd million except pharma gross oper incom pre-tax incom tax net incom dilut share dilut incom incom growth profit global
global pharmaceut compani product core categori includ diabet cancer vaccin hospit acut care
human health well anim health busi
consensu estim sale forecast top-lin compound growth
within health sale mrk keytruda gardasil expect deliv consensu sale
respect repres compound growth
note low level medium level high level base compani guidanc clinicaltri gov primari complet date
page analyst certif import disclosur
preview look gardasil overal keytruda oversea upsid
one-tim loss may hit ep confer call estimate
gsr vs consensu million except ep
sale forecast street
anticip contd momentum gardasil keytruda partial off-set
declin januvia franchis sale base review trend
believ gardasil beat forecast point iqvia
symphoni sale typic overst keytruda sale impli sale
slightli estimate said expect ou keytruda sale growth
strong januvia franchis high-singl digit volum declin
along sustain price pressur drag
ep estimate consensu due one-tim
ventur invest loss expect bring incom near-zero
believ incorpor consensu
sale ep est respect
mid-point sale near low-end mrk ep guidanc
focu call
iqvia/symphoni script analysi us sale
note unit except ep
see off-label use keytruda inlyta axitinib sinc
rcc data commun publish februari
expect new standard care
first top-line readout pneumococc conjug
vaccin expect year also receiv btd statu
pediatr popul could updat us differenti
strategi given pfe btd adult prevnar
last earn call compani mention result
combin avail soon
could discuss near-term long-term strategi hiv
core plan
page analyst certif import disclosur
mrk outlook beyond solid keytruda gardasil main driver
januvia tnf franchis declin pt rais
outlook pt increas
vs million except ep
rais pt base increas sale
keytruda vs prior estimate gardasil
vs prior estimate
keytruda rapid growth continu w/ label expans
tumor throughout global market estim sale
grow moder
compound-annual-growth-rate end keytruda royalti payment
boost gross margin bp year
forecast compound growth gardasil
forecast mrk overal sale flattish impact
januvia loe sale drop thru
consensu ev/ebit
among small cell lung kidney metastat triple-neg
breast cancer like biggest increment driver
keytruda growth
expect data keytruda adjuv set beyond
breast cancer emerg variou trial tumor type
potenti expand adjuv use
new indic excit lynparza
lenvima combin therapi
point appreci market opti
discuss market opti gefipix challeng
develop market toler issu note
page analyst certif import disclosur
view support
keytruda domin posit nsclc continu label expans multipl addit solid tumor well intenational
partner product lenvima lynparza deliv combin peak end-us sale
despit limit number late-stag pipelin opportun success grow thru loss januvia
increas emphasi mrk earli stage develop opportun success advanc ph studi part
daili treatment regimen enter mid-stag studi long-act depot formul
increas sale estim keytruda gardasil dcf-base price target current
net estim chang forecast sale profit global pharma discount rate
assum termin growth rate
deceler gardasil growth
neg keytruda readout next month
chang price environ oncolog drug
page analyst certif import disclosur
page analyst certif import disclosur
financi modelcagrcagr usd million except gross oper incom pre-tax incom tax net incom share dilut incom incom growth profit global
novarti global biopharmaceut compani base basel switzerland spin-off alcon eye care apr
novarti becom pureplay therapeut busi current two main segment innov medicin sandoz specialti
consensu forecast novn sale innov medicin im busi repres total sale
within im unit cosentyx entresto oncolog portfolio current revenu driver along recent launch aimovig
partner novn recent approv mayzent relaps secondari progress ms offset growth
opportun declin sale lucenti afinitor loe gilenya potl loe mid
 although ipr rule gilenya dose patent could block gener sever year
page analyst certif import disclosur
due plan spin-off alcon novn treat
discontinu busi accordingli novn forecast
expect pharma revenu ep sale
mainli driven uptak gilenya cosentyx oncolog
portfolio partial off-set fx headwind
sale includ cer revenue growth innov
medicin unit line novn mid-singl digit sale growth
guidanc ep higher consensu
could explain limit number post-alcon forecast
base us volum demand price analysi cosentyx
entresto meet sale estimate given strong yoy growth
respect
iqvia/symphoni script analysi us sale
focu call
regard recent legal disput w/ aimovig
recommend treat asset model go forward
updat time sandoz transit manufactur
contract aldr seem estimate compens exit could
quit substanti
launch mayzent us earli feedback
get payer physician segment
uniqu suit earli mayzent adopt
approach fda approv may realist
expect broad label newborn regardless genotyp
phenotyp data expect upcom
confer may expect see much efficaci data
patient dose intrathec
guggenheim secur llc estim compani report factset iqvia symphoni health price rx note unit except ep
page analyst certif import disclosur
expect growth innov drug cosentyx mayzent
drive sale reflect
compound-annual-growth-rate also expect oper margin improv given
mgmt state commit margin result compound-annual-growth-rate
ep period
expect flattish growth mainli due loe key
asset total combin sale declin estim
entresto gilenya lucenti
expect novn remain activ busi develop recent
comment ceo va narasimhan point smaller tuck deal
forecast total sale pipelin drug larg
offset impact
novn consensu ev/ebit
guggenheim secur llc estim compani report factset note unit except ep
iv therapi get approv sma type
symptomat sma infant intrathec deliveri older patient
approv novel payment scheme necessari switch
system treatment spinraza
risdiplam realist novn plan manag
would take separ sandoz might enbrel
patent decis impact plan
among entresto hf-pef fevipipr sever eosinophil
asthma ofatumumab relaps ms crizanlizumab sickl
cell pain crisi signific durabl effect
sale novn plan oper margin improv
page analyst certif import disclosur
intrigu late-stag pipelin includ sever clinic de-risk asset age-rel macular degener
sma type
diversifi busi dozen uniqu line blockbust product well growth opportun sandoz market-lead
partial off-set impact afinitor gilenya increas competit cosentyx lucenti challeng
 sandoz busi
exclud alcon due spin-off apr fair valu rang novn forecast sale profit
use global pharmaceut compani discount rate termin growth rate
delay gener entri gilenya
better-than-expect uptak aimovig
cosentyx price competit headwind
ofatumumab fail ms phase trial
fail gain approv sma type
abl break aimovig partnership novn
page analyst certif import disclosur
page analyst certif import disclosur
financi modelcagrcagrfigur except product total gross oper incom oper incom financi income/expens incom tax net incom dilut share dilut incom incom incom growth profit global
novo nordisk global healthcar compani oper two busi unit
diabet obes account sale
biopharmaceut growth hormon hemophilia asset account remain busi
consensu forecast total sale dkk net margin
novo bellweth diabet global account sale follow sanofi critic import
novo futur success semaglutid overal franchis includ once-weekli ozemp oral semaglutid once-
daili victoza saxenda combin xultophi
page analyst certif import disclosur
rel line sale dkk
consensu ep forecast dkk consensu
dkk driven higher op ex assumpt busi
relat ozemp launch activ prepar anticip
launch oral semaglutid end
sale dkk impli cer growth
compar management guidanc cer growth ep dkk
consensu estim dkk
base iqvia script trend see low single-digit qoq volum
declin legaci insulin product tresiba could exceed
expect xultophi saxenda victoza could exceed
expect base us volum trend
gsr vs consensu dkk million except ep
iqvia/symphoni script analysi us sale
focu call
look ozemp earli launch dynam
market share access dynam evolv market
victoza ozemp rel expect
see oral semaglutid fit current treatment
paradigm think oral inject diabet
space see oral sema util launch
although esperoct approv fda feb
wont launch us due third parti
ip agreement role see play evolv
guggenheim secur llc estim compani report factset note unit dkk except ep
page analyst certif import disclosur
rais pt dkk mainli driven
step-up sale forecast oral semaglutid dkk
vs prior dkk driven uptak assumpt
growth busi like driven primarili
semaglutid franchis assum launch oral semaglutid
obes opportun driven clinic meaning benefit
semaglutid obes patient step trial read
start forecast sale growth
driven primarili growth
expect sale dkk partial off-set
continu declin legaci insulin franchis victoza
vs dkk million except ep
novo consensu ev/ebit
guggenheim secur llc estim compani report factset note unit except ep
market evolv victoza ozemp oral
semaglutid next year longer term rel
uptak access novo nordisk success convert
victoza patient ozemp much trulici ozemp
grow categori
could gener perhap even gener farxiga
import oral semaglutid drug choic
diversif diabet necess long-term
sustain growth novo nordisk doubl core
driver given breadth scale insulin
page analyst certif import disclosur
posit view novo nordisk reflect
novo global leadership posit diabet obes comprehens protein-bas portfolio best-in-class long-
act insulin tresiba once-weekli ozemp
expect price pressur stabil long-act insulin benefit novo tresiba xultophi franchis
expect ozemp uptak acceler potenti regulatori approv oral semaglutid drive renew interest novo
upsid could come growth obes
higher sale forecast oral semaglutid valu novo dkk prior dkk dcf base
valuat assum wacc line larg cap pharma peer termin growth rate
price pressur diabet persist overhang novo busi
clinic failur regulatori delay next gener oral
page analyst certif import disclosur
page analyst certif import disclosur
financi modelcagrcagrdkk million except ep gross oper incom incom /expens pre-tax net incom dilut share dilut incom incom growth profit global
sanofi global pharmaceut compani oper global busi unit diabet cardiovascular diseas specialti care
vaccin gener medicin emerg market consum healthcar chc
consensu estim san sale forecast top-lin compound growth
pharmaceut segment consist specialti care diabet cardiovascular diseas consum product expect
street deliv total estim sale
area focu next month evolut rare disord franchis includ number potenti catalyst
includ launch uptak cablivi sutimlimab phase cad phase olipudas
page analyst certif import disclosur
san forecast sale ep respect
rel in-line consensu sale
consensu ep
line consensu sale
consensu ep driven higher op ex compani expect
grow cer next coupl year currenc
analysi show fx tailwind balanc year line
commun
base us volum demand price analysi dupix track
meet estim us prescript growth remain strong
yoy q/q growth easi comp due destock
aubagio high-singl digit yoy volum growth good net price
challeng put us touch consensu
gsr vs consensu million except ep
us script analysi million
focu call
san collabor develop beta
thalassemia given recent posit result
discuss san plan acceler sickl cell program
san view evolut beta thal market next
year role see play
venglustat could repres meaning opportun number
diseas help us understand near-term data
catalyst mileston
fda zynquista impact
zynquista develop progress type diabet
san commit contd develop
note unit except ep
page analyst certif import disclosur
vs million except ep
expect san show low stabl growth medium-term
long-term compound-annual-growth-rate
expect dupix increas
compound-annual-growth-rate partial off-set sale eros aubagio follow
loe forecast rel stabl chc vaccin sale
san sever interest late-stag drug candid
venglustat sutimlimab fitusiran isatuximab forecast modest
pipelin sale pharma sale year
reflect cautiou view isatuximab multipl myeloma
fitusiran hemophilia given competit dynam indic
san consensu ev/ebit
what net impact san revis price program insulin
us
payer primari driver admelog uptak
think peak share overal fast act market
segment could
within san rare diseas pipelin program
could transform profit
discuss ip around aubagio like time
gener enter major market around world
effort expand ms beyond aubagio lemtrada
page analyst certif import disclosur
opportun invest rare diseas genzym legaci portfolio newli acquir asset ablynx bioverativ
partnership
bioverativ hemophilia asset provid commerci platform rnai pipelin asset fitusiran phase hemophilia
face seriou challeng roch hemlibra time gene therapi
partnership produc three asset includ multi-billion dollar potl blockbust dupix expect
multipl new product compet share atop dermat asthma market potenti cap growth
fair valu rang sanofi base dcf-base valuat sale profit assum
wacc line larg cap pharma peer termin growth rate
upsid risk valuat includ reacceler dupix launch asthma better expect
launch cablivi rare blood disord attp libtayo cutan squamou cell carcinoma
downsid risk includ lower expect dupix growth greater expect insulin price pressur
impact toujeo greater expect eloct slowdown hemlibra
page analyst certif import disclosur
page analyst certif import disclosur
modelcagrcagrfigur except product total gross oper incom share profit loss associ joint minor busi oper incom income/expens incom tax net incom dilut share dilut incom incom growth profit april
page analyst certif import disclosur
usd million except ep
compani report guggenheim llc estim
page analyst certif import disclosur
